The insulin like growth factor-1 receptor (IGF-1R) as a drug target: Novel approaches to cancer therapy

Growth Hormone and IGF Research

Volumn 14, Issue 4, 2004, Pages 287-295

  Bähr, Corinna ^a   Groner, Bernd ^a  

^a Institute for Biomedical Research   (Germany)

Author keywords

Cancer; IGF 1R; Inhibition strategies; Peptide aptamers; Protein transduction; Targeted degradation

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; APTAMER; COMPLEMENTARY DNA; COMPLEMENTARY RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1H7; MONOCLONAL ANTIBODY 391; MONOCLONAL ANTIBODY 4G11; MONOCLONAL ANTIBODY A12; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; TYRPHOSTIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; HUMANS; NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 3042775027     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ghir.2004.02.004     Document Type: Review

References (86)

1. Ullrich A. Gray A. Tam A.W. et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity EMBO J. 5 1986 2503-2512
2. Le Roith D. Werner H. Breitner-Johnson D. Roberts C.T. Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor Endocr. Rev. 16 1995 143-163
3. Hubbard S.R. Till J.H. Protein tyrosine kinase structure and function Annu. Rev. Biochem. 69 2000 373-398
4. Kato H. Faria T.N. Stannard B. Roberts C.T. Jr. Le Roith D. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-mimetic antibody (alpha IR-3) J. Biol. Chem. 268 1993 2655-2661
5. Kato H. Faria T.N. Stannard B. Roberts C.T. Jr. Le Roith D. Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action Mol. Endocrinol. 8 1994 40-50
6. Navarro M. Baserga R. Limited redundancy of survival signals from the type I insulin-like growth factor receptor Endocrinology 142 2001 1073-1081
7. Liu J.P. Baker J. Perkins A.S. Robertson E.J. Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (igf-1) and type 1 IGF receptor (Igf1r) Cell 75 1993 59-72
8. Baker J. Liu J.P. Robertson E.J. Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor-1 (IGF-1) and type-1 IGF receptor (IGF1R) Cell 75 1993 59-72
9. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 55 1995 249-252
10. Sell C. Rubin M. Rubin R. Liu J.P. Efstratiadis A. Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type-1 IGF receptor Proc. Natl. Acad. Sci. USA 90 1993 11217-11221
11. Sell C. Dumenil G. Deveaud C. et al. Effect of a null mutation of the type I IGF receptor gene on growth and transformation of mouse embryo fibroblasts Mol. Cell Biol. 14 1994 3604-3612
12. Valentinis B. Morrione A. Taylor S.J. Baserga R. Insulin-like growth factor 1 receptor signaling in transformation by src oncogenes Mol. Cell Biol. 17 1997 3744-3754
13. Morrison K.B. Tognon C.E. Garnett M.J. Deal C. Sorensen P.H. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation Oncogene 21 2002 5684-5695
14. Werner H. Le Roith D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis Crit. Rev. Oncog. 8 1997 71-92
15. Stracke M.L. Engel J.D. Wilson L.W. Rechler M.M. Liotta L.A. Schiffmann E. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells J. Biol. Chem. 264 1989 21544-21549
16. Rubin R. Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity Lab. Invest. 73 1995 311-331
17. Resnik J.L. Reichart D.B. Huey K. Webster N.J. Seely B.L. Elevated insulin-like growth factor autophosphorylation and kinase activity in human breast cancer Cancer Res. 58 1998 1159-1164
18. Hellawell G.O. Turner G.D. Davies D.R. Poulsom R. Brewster S.F. Macaulay V.M. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease Cancer Res. 62 2002 2942-2950
19. Hakam A. Yeatman T.J. Lu L. et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer Hum. Pathol. 30 1999 1128-1133
20. Kanter-Lewensohn L. Dricu A. Girnita L. Wejde J. Larsson O. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins Growth Factors 17 2000 193-202
21. Nakamura K. Hongo A. Kodama J. Miyagi Y. Yoshinouchi M. Kudo T. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines Cancer Res. 60 2000 760-765
22. Resnicoff M. Sell C. Rubini M. et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors Cancer Res. 54 1994 2218-2222
23. Resnicoff M. Burgaud J.L. Rotman H.L. Abraham D. Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors Cancer Res. 55 1995 3739-3741
24. Neuenschwander S. Roberts C.T. Jr. Le Roith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor receptor antisense ribonucleic acid Endocrinology 136 1995 4298-4303
25. Long L. Rubin R. Baserga R. Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor Cancer Res. 55 1995 1006-1009
26. Chernicky C.L. Tan H. Yi L. Loret de Mola J.R. Ilan J. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo Mol. Pathol. 55 2002 102-109
27. Pavelic J. Pavelic L. Karadza J. et al. Insulin-like growth factor familiy and combined antisense approach in therapy of lung carcinoma Mol. Med. 8 2002 149-157
28. Chernicky C.L. Yi L. Tan H. Gan S.U. Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential and prolongs survival in vivo Cancer Gene. Ther. 7 2000 384-395
29. Scotlandi K. Maini C. Manara M.C. et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells Cancer Gene. Ther. 9 2002 296-307
30. Macaulay V.M. Salisbury A.J. Bohula E.A. Playford M.P. Smorodinsky N.I. Shiloh Y. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase Oncogene 20 2001 4029-4040
31. Liu X. Turbyville T. Fritz A. Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice Cancer Res. 58 1998 5432-5438
32. Andrews D.W. Resnicoff M. Flanders A.E. et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas J. Clin. Oncol. 19 2001 2189-2200
33. White P.J. Atley L.M. Wraight C.J. Antisense oligonucleotide treatments for psoriasis Expert Opin. Biol. Ther. 4 2004 75-81
34. Bohula E.A. Salisbury A.J. Sohail M. et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript J. Biol. Chem. 278 2003 15991-15997
35. Rininsland F. Johnson T.R. Chernicky C.L. Schulze E. Burfeind P. Ilan J. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells Proc. Natl. Acad. Sci. USA 94 1997 5854-5859
36. Baselga J. Clinical trial of Herceptin (R) (trastuzumab) Eur. J. Cancer 37 2001 18-24
37. Kull F.C.Jr. Jacobs S. Su Y.F. Svoboda M.E. Van Wyk J.J. Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin-C J. Biol. Chem. 258 1983 6561-6566
38. Rohlik Q.T. Adams D. Kull F.C. Jr. Jacobs S. An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture Biochem. Biophys. Res. Commun. 149 1987 276-281
39. Scotlandi K. Benini S. Nanni P. et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice Cancer Res. 58 1998 4127-4131
40. Benini S. Manara M.C. Baldini N. et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells Clin. Cancer Res. 7 2001 1790-1797
41. Hailey J. Maxwell E. Koukouras K. Bishop W.R. Pachter J.A. Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells Mol. Cancer Ther. 1 2002 1349-1353
42. Jackson-Booth P.G. Terry C. Lackey B. Lopaczynska M. Nissley P. Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation Horm. Metab. Res. 35 2003 850-856
43. Burtrum D. Zhu Z. Lu D. et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo Cancer Res. 63 2003 8912-8921
44. Li S.L. Liang S.J. Guo N. Wu A.M. Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth Cancer Immunol. Immunother. 49 2000 243-252
45. Sachdev D. Li S.L. Hartell J.S. Fujita-Yamaguchi Y. Miller J.S. Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I Cancer Res. 63 2003 627-635
46. Ye J.J. Liang S.J. Guo N. et al. Combined effects of tamoxifen and a chimeric humanized single chain antibody against type I IGF receptor on breast tumor growth in vivo Horm. Metab. Res. 35 2003 836-842
47. Pietrzkowski Z. Wernicke D. Porcu P. Jameson B.A. Baserga R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1 Cancer Res. 52 1992 6447-6451
48. Pietrzkowski Z. Mulholland G. Gomella L. Jameson B.A. Wernicke D. Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1 Cancer Res. 53 1993 1102-1106
49. Coppola D. Ferber A. Miura M. et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor Mol. Cell Biol. 14 1994 4588-4595
50. Favelyukis S. Till J.H. Hubbard S.R. Miller W.T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase Nat. Struct. Biol. 8 2001 1058-1063
51. Munshi S. Hall D.L. Kornienko M. Darke P.L. Kuo L.C. Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution Acta Crystallogr., D 59 2003 1725-1730
52. Párrizas M. Gazit A. Levitzki A. Wertheimer E. Le Roith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins Endocrinology 138 1997 1427-1433
53. Blum G. Gazit A. Levitzki A. Substrate competitive inhibitors of IGF-1 receptor kinase Biochemistry 39 2000 15705-15712
54. Blum G. Gazit A. Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics J. Biol. Chem. 278 2003 40442-40454
55. Girnita A. Girnita L. del Prete F. Bartolazzi A. Larsson O. Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth Cancer Res. 64 2004 236-242
56. Burgaud J.L. Resnicoff M. Baserga R. Mutant IGF-I receptors as dominant negatives for growth and transformation Biochem. Biophys. Res. Commun. 214 1995 475-481
57. Heron-Milhavet L. Karas M. Goldsmith C.M. Baum B.J. Le Roith D. Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair J. Biol. Chem. 276 2001 18185-18192
58. Seely B.L. Samimi G. Webster N.J. Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo BMC Cancer 2 2002 15
59. Scotlandi K. Avnet S. Benini S. et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells Int. J. Cancer 101 2002 1-16
60. Blakesley V.A. Kalebic T. Helman L.J. et al. Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I-receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor Endocrinology 137 1996 410-417
61. Brodt P. Fallavollita L. Khatib A.M. Samani A.A. Zhang D. Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor β subunit J. Biol. Chem. 276 2001 33608-33615
62. Adachi Y. Lee C.T. Coffee K. et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer lines Gastroenterology 123 2002 1191-1204
63. Min Y. Adachi Y. Yamamoto H. et al. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer Cancer Res. 63 2003 6432-6441
64. Lee C.T. Park K.H. Adachi Y. et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer Cancer Gene. Ther. 10 2003 57-63
65. Reiss K. D'Ambrosio C. Tu X. Tu C. Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect Clin. Cancer Res. 4 1998 2647-2655
66. Reiss K. Tu X. Romano G. Peruzzi F. Wang J.Y. Baserga R. Intracellular association of a mutant insulin-like growth factor receptor with endogenous receptors Clin. Cancer Res. 7 2001 2134-2144
67. Wu J. Haugk K. Plymate S.R. Activation of pro-apoptotic p38-pathway in the prostate cancer cell line M12 expressing a truncated IGF-1R Horm. Metab. Res. 35 2003 751-757
68. Sachdev D. Hartell J.S. Lee A.V. Zhang X. Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells J. Biol. Chem. 279 2004 5017-5024
69. O'Connor R. Kauffmann-Zeh A. Liu Y. et al. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis Mol. Cell Biol. 17 1997 427-435
70. Liu Y. Lehar S. Corvi C. Payne G. O'Connor R. Expression of the insulin-like growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells Cancer Res. 58 1998 570-576
71. Hongo A. Yumet G. Resnicoff M. Romano G. O'Connor R. Baserga R. Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by stable expression of a myristylated COOH terminus of the insulin-like growth factor I receptor Cancer Res. 58 1998 2477-2484
72. Colas P. Cohen B. Jessen T. Grishina I. McCoy J. Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2 Nature 380 1996 548-550
73. Norman T.C. Smith D.L. Sorger P.K. et al. Genetic selection of peptide inhibitors of biological pathways Science 285 1999 591-595
74. Fabbrizio F. Le Cam L. Polanowska J. et al. Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity Oncogene 18 1999 4357-4363
75. Zutshi R. Brickner M. Chmielewski J. Inhibiting the assembly of protein-protein interfaces Curr. Opin. Chem. Biol. 2 1998 62-66
76. Butz K. Denk C. Fitscher B. et al. Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity Oncogene 20 2001 6579-6586
77. Xu C.W. Luo Z. Inactivation of Ras function by allele-specific peptide aptamers Oncogene 21 2002 5753-5757
78. Buerger C. Nagel-Wolfrum K. Kunz C. et al. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells J. Biol. Chem. 278 2003 37610-37621
79. K. Nagel-Wolfrum, C. Buerger, I. Wittig, F. Hoppe-Seyler, B. Groner, The interaction of specific peptide aptamers with the DNA binding domain and the dimerisation domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells, Mol. Cancer Res., in press
80. Schwarze S.R. Dowdy S.F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA Trends Pharmacol. Sci. 21 2000 45-48
81. Futaki S. Suzuki T. Ohashi W. et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery J. Biol. Chem. 276 2001 5836-5840
82. Adams T.E. Epa V.C. Garrett T.P.J. Ward C.W. Structure and function of the type 1 insulin-like growth factor receptor Cell Mol. Life Sci. 57 2000 1050-1093
83. Hilton D.J. Richardson R.T. Alexander W.S. Twenty proteins containing a C-terminal SOCS box from five structural classes Proc. Natl. Acad. Sci. USA 95 1998 114-119
84. Zhang J.G. Farley A. Nicholson S.E. et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteosomal degradation Proc. Natl. Acad. Sci. USA 96 1999 2071-2076
85. Buerger C. Groner B. Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling J. Cancer Res. Clin. Oncol. 129 2003 669-675
86. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor receptor Oncogene 22 2003 6589-6597